Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

Journal of Virology

Volumn 75, Issue 16, 2001, Pages 7470-7480

  Hofmann Lehmann, R ^a   Vlasak, J ^a   Rasmussen, R A ^a   Smith, B A ^a   Baba, T W ^a   Liska, V ^a   Ferrantelli, F ^a   Montefiori, D C ^a   McClure, H M ^a   Anderson, D C ^a   Bernacky, B J ^a   Rizvi, T A ^a   Schmidt, R ^a   Hill, L R ^a   Keeling, M E ^a   Katinger, H ^a   Stiegler, G ^a   Cavacini, L A ^a   Posner, M R ^a   Chou, T C ^a   Andersen, J ^a   Ruprecht, R M ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY F105; MONOCLONAL ANTIBODY IGG1B12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MACACA; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PERINATAL PERIOD; PERSISTENT INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VERTICAL TRANSMISSION; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; DRUG SYNERGISM; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION, PASSIVE; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0034904087     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.16.7470-7480.2001     Document Type: Article

References (64)

1. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection
2. Mucosal infection of neonatal rhesus monkeys with cell-free SIV
3. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
4. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
5. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine
6. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia
7. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
8. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
9. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
10. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
11. Designing CD4 immunoadhesins for AIDS therapy
12. The median-effect principle and the combination index for quantitation of synergism and antagonism
13. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors
14. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
15. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1
16. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
17. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
18. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
19. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
20. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo
21. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
22. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
23. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: Comparison of one- vs. two-enzyme systems
24. + cells in SHIV-infected macaques
25. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques
26. + lymphocyte depletion in rhesus monkeys
27. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
28. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins
29. + by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
30. Persistent infection of macaques with simian-human immunodeficiency viruses
31. Detection of simian T cell leukemia virus type I infection in seronegative macaques
32. Viremia and AIDS in rhesus macaques after intramuscular inoculation of plasmid DNA encoding full-length SIVmac239
33. Simultaneous detection of simian retrovirus type D serotypes 1, 2, and 3 by polymerase chain reaction
34. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS
35. Utility of SHIV for testing HIV-1 vaccine candidates in macaques
36. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
37. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
38. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event
39. HIV transmission through breastfeeding: A study in Malawi
40. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
41. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
42. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
43. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
44. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
45. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial
46. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1
47. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis
48. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection
49. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease
50. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
51. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
52. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses
53. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
54. Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection
55. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
56. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
57. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates
58. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques
59. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change
60. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
61. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
62. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
63. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens